<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Novacyt — News on 6ix</title>
    <link>https://6ix.com/company/novacyt</link>
    <description>Latest news and press releases for Novacyt on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 20 Mar 2026 07:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/novacyt" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836160178dffbe2df13cf36.webp</url>
      <title>Novacyt</title>
      <link>https://6ix.com/company/novacyt</link>
    </image>
    <item>
      <title>Result of Preferential Subscription Rights Issue</title>
      <link>https://6ix.com/company/novacyt/news/result-of-preferential-subscription-rights-issue</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/result-of-preferential-subscription-rights-issue</guid>
      <pubDate>Fri, 20 Mar 2026 07:00:00 GMT</pubDate>
      <description>Novacyt S.A. has successfully raised €784,736 through a preferential subscription rights issue, issuing 1,961,840 new ordinary shares at €0.40 each, following its acquisition of Southern Cross Diagnostics Pty Ltd. The offer was oversubscribed by 125.20%, with total demand reaching 2,456,286 new shares. Ardenna PTY Ltd subscribed for €478,526 and was allocated the remaining 1,041,348 unsubscribed shares, resulting in it holding 1.43% of the enlarged share capital. The net proceeds of approximatel</description>
    </item>
    <item>
      <title>Preferential Subscription Rights Issue</title>
      <link>https://6ix.com/company/novacyt/news/preferential-subscription-rights-issue</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/preferential-subscription-rights-issue</guid>
      <pubDate>Mon, 02 Mar 2026 07:02:00 GMT</pubDate>
      <description>Novacyt S.A. is undertaking a rights issue to raise up to €784,736 by offering new shares at €0.40 each, on a 1-for-36 basis, with a subscription period from March 6 to March 17, 2026. The company has secured subscription commitments totaling €605,826, representing over 75% of the planned capital increase, including contributions from Ardenna PTY LTD (€478,526) and members of the Board (€117,300). This capital raise aims to strengthen the company&apos;s balance sheet following the acquisition of Sout</description>
    </item>
    <item>
      <title>Acquisition of Southern Cross Diagnostics</title>
      <link>https://6ix.com/company/novacyt/news/acquisition-of-southern-cross-diagnostics</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/acquisition-of-southern-cross-diagnostics</guid>
      <pubDate>Mon, 23 Feb 2026 07:00:00 GMT</pubDate>
      <description>Novacyt S.A. has conditionally agreed to acquire Southern Cross Diagnostics Pty Ltd for an initial cash consideration of AUD$8.5m (approximately £4.4m), a move expected to be immediately earnings and revenue accretive. Southern Cross Diagnostics, a profitable Australian distributor, reported revenues of circa £6.7m and a net profit of circa £0.8m for the year ended June 2025, and its acquisition provides Novacyt direct access to the growing Australian diagnostic market. The transaction also incl</description>
    </item>
    <item>
      <title>Liquidity Agreement Monthly Update and TVR</title>
      <link>https://6ix.com/company/novacyt/news/liquidity-agreement-monthly-update-and-tvr</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/liquidity-agreement-monthly-update-and-tvr</guid>
      <pubDate>Mon, 02 Feb 2026 15:45:00 GMT</pubDate>
      <description>Novacyt S.A. has provided its monthly update on the liquidity agreement, reporting that between January 1 and January 31, 2026, Invest Securities purchased 11,018 ordinary shares and sold 16,569 ordinary shares, with prices ranging from €0.39 to €0.45. As of January 31, 2026, the company holds 113,915 ordinary shares in treasury. The total number of ordinary shares in issue is 70,626,248, which shareholders can use for notification calculations.
                Disclaimer*</description>
    </item>
    <item>
      <title>NIPT Tender Award</title>
      <link>https://6ix.com/company/novacyt/news/nipt-tender-award</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/nipt-tender-award</guid>
      <pubDate>Tue, 27 Jan 2026 07:00:00 GMT</pubDate>
      <description>Novacyt S.A. announced that its subsidiary, Yourgene Health UK Ltd, has been awarded a two-year contract, with an option for a further two years, by St George&apos;s University Hospitals NHS Foundation Trust for the provision of Non-Invasive Prenatal Testing (NIPT) using its IONA® Nx NIPT Workflow. This contract represents a continuation of existing business and serves approximately one third of the NHS maternity services population in England, with the CEO highlighting the quality of their product a</description>
    </item>
    <item>
      <title>Full year trading update</title>
      <link>https://6ix.com/company/novacyt/news/full-year-trading-update-12</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/full-year-trading-update-12</guid>
      <pubDate>Wed, 21 Jan 2026 07:00:00 GMT</pubDate>
      <description>Novacyt S.A. announced an unaudited full-year trading update for 2025, with revenues of approximately £20.0 million, meeting market expectations and showing sequential half-year revenue growth. The Clinical segment generated £13.8 million in sales, driven by a new APAC customer and over 10% growth in NIPT technologies, while the Instrumentation segment saw over 25% growth to £2.5 million, primarily due to the LightBench® Discover instrument. The RUO segment declined by approximately 10% to £3.7 </description>
    </item>
    <item>
      <title>Strategy update &amp; notice of investor presentation</title>
      <link>https://6ix.com/company/novacyt/news/strategy-update-and-notice-of-investor-presentation</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/strategy-update-and-notice-of-investor-presentation</guid>
      <pubDate>Wed, 22 Oct 2025 06:00:00 GMT</pubDate>
      <description>Novacyt S.A. anticipates a slight increase in H2 2025 revenues compared to H1 2025, driven by instrument sales. The Group expects an improved EBITDA loss for 2025 compared to the £9.1m loss reported in FY24, supported by a better gross margin. Cash outflow is also projected to improve in H2 2025, being lower than the H1 2025 outflow of £6.8m, due to completed site consolidation. The company aims for double-digit revenue growth year-on-year from FY26 and a gross margin above 60% each year, noting</description>
    </item>
    <item>
      <title>2025 Interim results</title>
      <link>https://6ix.com/company/novacyt/news/2025-interim-results-3</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/2025-interim-results-3</guid>
      <pubDate>Tue, 30 Sep 2025 06:00:00 GMT</pubDate>
      <description>Novacyt S.A. announced its unaudited interim results for the six months ended 30 June 2025. Underlying Group revenue grew by approximately 2%, or 4% on a constant currency basis, excluding the Taiwan service laboratory divestment. The Group&apos;s statutory revenue for H1 2025 was £9.8 million, slightly down from £10.0 million in H1 2024, but the NIPT Technologies segment increased 10% year-on-year to £2.4 million. The APAC region saw a growth of approximately 9%. The Group&apos;s gross margin remained st</description>
    </item>
    <item>
      <title>Notice of Results</title>
      <link>https://6ix.com/company/novacyt/news/notice-of-results-92</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/notice-of-results-92</guid>
      <pubDate>Thu, 18 Sep 2025 06:00:00 GMT</pubDate>
      <description>Novacyt S.A. will release its unaudited interim results for the six months ending June 30, 2025, on Tuesday, September 30, 2025. The international molecular diagnostics company, listed on EURONEXT GROWTH: ALNOV and AIM: NCYT, has a broad portfolio of integrated technologies and services.

                Disclaimer*</description>
    </item>
    <item>
      <title>Appointment of Joint Corporate Broker</title>
      <link>https://6ix.com/company/novacyt/news/appointment-of-joint-corporate-broker-32</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/appointment-of-joint-corporate-broker-32</guid>
      <pubDate>Mon, 15 Sep 2025 06:00:00 GMT</pubDate>
      <description>Novacyt S.A. announced the appointment of Singer Capital Markets as a joint corporate broker, effective immediately. Singer Capital Markets will collaborate with SP Angel, the company&apos;s existing Nominated Adviser and joint corporate broker. Novacyt is listed on EURONEXT GROWTH: ALNOV and AIM: NCYT. The company is headquartered in Le Vésinet, France, with offices in the UK, Singapore, the US, and Canada, and has a commercial presence in over 65 countries.

                Disclaimer*</description>
    </item>
    <item>
      <title>Resolution re. Lab 21 HSE Prosecution</title>
      <link>https://6ix.com/company/novacyt/news/resolution-re-lab-21-hse-prosecution</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/resolution-re-lab-21-hse-prosecution</guid>
      <pubDate>Fri, 12 Sep 2025 09:00:00 GMT</pubDate>
      <description>Novacyt S.A. announced the resolution of the Health and Safety Executive prosecution against its non-trading subsidiary, Lab 21 Healthcare Ltd, concerning the use of biological agents at its Axminster site between June 2018 and April 2019. Lab 21, having previously pleaded guilty to health and safety charges, was ordered to pay a fine of £52,000. The company stated that the fine will be paid from existing cash resources and will not materially affect the Group&apos;s financial position. With the paym</description>
    </item>
    <item>
      <title>Liquidity Agreement Monthly Update &amp; TVR</title>
      <link>https://6ix.com/company/novacyt/news/liquidity-agreement-monthly-update-and-tvr-1</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/liquidity-agreement-monthly-update-and-tvr-1</guid>
      <pubDate>Fri, 01 Aug 2025 15:02:00 GMT</pubDate>
      <description>Liquidity Agreement Monthly Update &amp; TVR.</description>
    </item>
    <item>
      <title>Half-year trading update</title>
      <link>https://6ix.com/company/novacyt/news/half-year-trading-update-12</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/half-year-trading-update-12</guid>
      <pubDate>Tue, 29 Jul 2025 06:00:00 GMT</pubDate>
      <description>Half-year trading update.</description>
    </item>
    <item>
      <title>Launch of LightBench® Discover</title>
      <link>https://6ix.com/company/novacyt/news/launch-of-lightbenchr-discover</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/launch-of-lightbenchr-discover</guid>
      <pubDate>Tue, 15 Jul 2025 06:00:00 GMT</pubDate>
      <description>Launch of LightBench® Discover.</description>
    </item>
    <item>
      <title>Result of AGM</title>
      <link>https://6ix.com/company/novacyt/news/result-of-agm-237</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/result-of-agm-237</guid>
      <pubDate>Fri, 20 Jun 2025 06:00:00 GMT</pubDate>
      <description>Result of AGM.</description>
    </item>
    <item>
      <title>Publication of Annual Report</title>
      <link>https://6ix.com/company/novacyt/news/publication-of-annual-report-5</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/publication-of-annual-report-5</guid>
      <pubDate>Mon, 16 Jun 2025 06:00:00 GMT</pubDate>
      <description>Publication of Annual Report.</description>
    </item>
    <item>
      <title>Liquidity Agreement and Total Voting Rights</title>
      <link>https://6ix.com/company/novacyt/news/liquidity-agreement-and-total-voting-rights</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/liquidity-agreement-and-total-voting-rights</guid>
      <pubDate>Mon, 02 Jun 2025 10:30:00 GMT</pubDate>
      <description>Liquidity Agreement and Total Voting Rights.</description>
    </item>
    <item>
      <title>AGM Voting</title>
      <link>https://6ix.com/company/novacyt/news/agm-voting</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/agm-voting</guid>
      <pubDate>Wed, 28 May 2025 06:00:00 GMT</pubDate>
      <description>AGM Voting.</description>
    </item>
    <item>
      <title>Notice of AGM</title>
      <link>https://6ix.com/company/novacyt/news/notice-of-agm-109</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/notice-of-agm-109</guid>
      <pubDate>Mon, 12 May 2025 06:00:00 GMT</pubDate>
      <description>Notice of AGM.</description>
    </item>
    <item>
      <title>Full Year 2024 Results</title>
      <link>https://6ix.com/company/novacyt/news/full-year-2024-results</link>
      <guid isPermaLink="true">https://6ix.com/company/novacyt/news/full-year-2024-results</guid>
      <pubDate>Wed, 30 Apr 2025 06:00:00 GMT</pubDate>
      <description>Full Year 2024 Results.</description>
    </item>
  </channel>
</rss>